
Opinion|Videos|November 11, 2024
Comparing Dosing Schedules With Standard Therapies
Author(s)Joshua K. Sabari, MD
Joshua K. Sabari, MD, discusses how the dosing schedule of ifinatamab deruxtecan offers advantages in terms of simplicity and treatment adherence vs topotecan and lurbinectedin, suggesting that it may enhance the overall quality of life for patients undergoing treatment for SCLC.
Advertisement
Episodes in this series

Video content above is prompted by the following:
In terms of simplicity, treatment adherence, and quality of life, how does the dosing schedule of ifinatamab deruxtecan compare with those of topotecan and lurbinectedin?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Blinatumomab Plus Chemo Show Improved Survival in Infants with KMT2A-r ALL
2
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
3
Evaluating the Molecular Landscape in Endometrial Cancer to Optimize Treatment
4
Bria-IMT Shows Extended Survival in Advanced Metastatic Breast Cancer
5
















